Virtual Grand Rounds
Multiple Sclerosis Virtual Grand Rounds is a monthly, case-based CME-certified webcast series designed to provide health care providers with the most current information about the identification, management, and treatment of patients with MS, with the goal of improving clinical outcomes and enhancing patient quality of life. The overall goal of this series is to enhance participants' knowledge, competence, and skills in the best clinical practices in the care of patients with MS.
Additionally, the Ask the Experts and Multiple Sclerosis Challenge provides health care professionals a simple and convenient method to pose related questions for the faculty, discuss cases, and exchange information, as well as participate in an interactive case polling challenge to test knowledge.
Release Date: July 15, 2014
Expiration Date: July 15, 2015
Richard Ransohoff, MD
Release Date: June 17, 2014
Expiration Date: June 17, 2015
Release Date: May 15, 2014
Expiration Date: May 15, 2015
Bruce D. Trapp, PhD
Release Date: April 15, 2014
Expiration Date: April 15, 2015
Alasdair Coles, PhD, FRCP
Release Date: February 13, 2014
Expiration Date: February 13, 2015
Release Date: November 15, 2013
Expiration Date: November 15, 2014
- Summarize recent research on the pathology, pathogenesis, and epidemiology of MS and assess their impact on clinical practices.
- Describe the epidemiology of MS and the diagnostic criteria, treatment, and challenges in children.
- Review research on Devic’s disease pathophysiology, epidemiology, and clinical expression and explain its impact on diagnosis, imaging, and treatment of the disease.
- Define optic neuritis, its pathology, clinical characteristics, appropriate imaging studies, diagnosis, and treatment options.
- Describe evidence supporting use of optical coherence tomography (OCT) technology to monitor for macular edema in patients receiving fingolimod therapy.
- Describe pros and cons of MRI use as an imaging study in the diagnosis of MS.
- Describe how to effectively manage adverse events risks when shifting from relatively safe but less effective agents to more effective biologic agents with more extensive risk profiles.
- Appropriately assess risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab treatment.
- Critically appraise efficacy and side effects of new agents for MS and describe monitoring strategies to mitigate risks in patients.
- Define the terms disease-free state and treat to target, their measurement, and their roles in clinical practice.
This educational series is designed for neurologists and other health care professionals who manage patients with multiple sclerosis.
Alexander D. Rae-Grant, MD
Clinical Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director of Resident and Student Education
Mellen Center for Multiple Sclerosis Treatment and Research